CASI Pharmaceuticals, Inc. (CASIF): Capital Expenditures
$16.0K
Year ended 2025-12-31
-85.8%
3-year compound annual growth
-59.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.0K | -92.8% | 2026-05-15, From 2025-01-01 |
| 2024-12-31 | $223.0K | +9.3% | 2026-05-15, From 2024-01-01 |
| 2023-12-31 | $204.0K | -96.4% | 2026-05-15, From 2023-01-01 |
| 2022-12-31 | $5.61M | -37.3% | 2025-03-31, From 2022-01-01 |
| 2021-12-31 | $8.95M | +496.7% | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | $1.50M | n/a | 2023-04-26, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $16.0K | -92.8% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $5.0K | -64.3% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $47.0K | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $246.0K | -63.4% |
| Alumis Inc. (ALMS) | 2025-12-31 | $653.0K | -62.3% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $1.04M | -67.0% |
| Celularity Inc (CELU) | 2024-12-31 | $161.0K | -84.6% |
| uniQure N.V. (QURE) | 2025-12-31 | $439.0K | -87.0% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $177.0K | +168.2% |
Compare CASIF, EVFM, SLGL, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗